MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on AARP Medicare Rx Saver from UHC (S5921-361)

Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), Wisconsin
Premium
$0.00/month
Deductible
$615.00
Change plan

3 of 9 IL-17 and IL-23 biologics are covered on this plan. All 3 require prior authorization.

6 aren't on the formulary, including Stelara and ustekinumab biosimilars.

  • Skyrizi
    risankizumab
    Covered · prior auth
    from $2,511.88
    Tier 5
  • Tremfya
    guselkumab
    Covered · prior auth
    from $3,872.04
    Tier 5
  • Cosentyx
    secukinumab
    Covered · prior auth
    from $10,382.17
    Tier 5
Not on the formulary
Stelara, ustekinumab biosimilars, Wezlana, Selarsdi, Taltz, Bimzelx

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list